Elite Journal of Laboratory Medicine. Volume 2 Issue 6(2024), Pp. 49-66
https://epjournals.com/journals/EJLM

Immune Dysregulation in HIV-Positive Neonates: A Review

Emmanuel Ifeanyi Obeagu

Department of Medical Laboratory Science, Kampala International University, Uganda, emmanuelobeagu@yahoo.com

Abstract

Human Immunodeficiency Virus (HIV) infection in neonates presents significant challenges due to the immaturity of their immune systems and the profound impact of the virus on immune regulation. This review explores the mechanisms of immune dysregulation in HIV-positive neonates, focusing on immune cell dysfunction, cytokine imbalances, and the effects of antiretroviral therapy (ART). The interplay between these factors results in chronic immune activation, inflammation, and compromised immune responses, which contribute to increased vulnerability to infections and other health complications in this vulnerable population. Key aspects of immune dysregulation include abnormalities in T cells, B cells, and innate immune cells, leading to impaired immune function and increased susceptibility to opportunistic infections. Elevated levels of pro-inflammatory cytokines such as IL-6 and TNF-α, alongside dysregulated anti-inflammatory cytokines like IL-10, perpetuate a state of chronic inflammation. Early initiation of ART is crucial for reducing viral load and limiting immune damage, but residual immune activation and incomplete immune reconstitution remain challenges that require further investigation.

Keywords*: HIV, neonates, immune dysregulation, cytokines, antiretroviral therapy, immune cells, inflammation*

Introduction

Human Immunodeficiency Virus (HIV) infection continues to pose significant global health challenges, particularly affecting vulnerable populations such as neonates. Neonatal HIV infection occurs predominantly through vertical transmission from infected mothers during pregnancy, childbirth, or breastfeeding. Despite advancements in prevention strategies and antiretroviral therapy (ART), neonates remain at risk of acquiring HIV, leading to lifelong implications for their immune development and overall health.[1] The neonatal period is characterized by rapid immune system development, essential for protecting against infections encountered early in life. However, HIV disrupts this delicate process by directly targeting key immune cells, primarily CD4+ T lymphocytes, which play a central role in coordinating immune responses. HIV infects and

depletes CD4+ T cells, compromising the immune system's ability to mount effective responses against pathogens. This depletion is particularly detrimental in neonates, where immune cell numbers and functions are still maturing.[2-3] Immune dysregulation in HIV-positive neonates encompasses a spectrum of abnormalities that affect both innate and adaptive immune responses. Beyond CD4+ T cell depletion, HIV infection alters the function of other immune cells, including B cells, natural killer (NK) cells, dendritic cells, and macrophages. These alterations impair immune surveillance and response mechanisms, contributing to increased susceptibility to infections. Furthermore, HIV-induced immune activation leads to the production of pro-inflammatory cytokines and chemokines, creating a state of chronic inflammation that further exacerbates immune dysfunction.[4-8] The pathogenesis of HIV in neonates involves complex interactions between the virus and the developing immune system. Upon exposure to HIV, neonatal immune cells may respond differently compared to adults, influenced by factors such as immune immaturity, maternal HIV-specific antibodies, and unique immune cell subsets. [9-10]

Antiretroviral therapy (ART) has revolutionized the management of HIV infection by suppressing viral replication and preserving immune function. Early initiation of ART in neonates significantly reduces the risk of disease progression and improves survival outcomes. However, the impact of ART on immune reconstitution in neonates is not fully understood, and challenges such as drug resistance and long-term immune sequelae persist. Optimizing ART regimens and exploring adjunctive therapies to modulate immune activation are critical for enhancing treatment efficacy and minimizing long-term complications in HIV-positive neonates.[11-15] The immune responses in HIV-infected neonates are further complicated by the presence of co-infections and coinfections, such as tuberculosis (TB) and hepatitis B and C viruses (HBV and HCV). These infections can exacerbate immune dysregulation, complicate treatment strategies, and increase the risk of adverse health outcomes. Co-infections may also influence immune responses to HIV and impact the efficacy of ART, necessitating integrated management approaches that address multiple pathogens concurrently.[16-17] Beyond immediate clinical implications, immune dysregulation in HIV-positive neonates has long-term consequences on growth, development, and neurocognitive function. Chronic immune activation and inflammation are associated with neurodevelopmental delays and cognitive impairments, affecting the quality of life and socio-economic outcomes in affected individuals.[18-19] Addressing immune dysregulation in HIV-positive neonates requires a multifaceted approach that integrates advances in virology, immunology, and pediatric medicine. Research efforts aimed at elucidating the mechanisms of immune dysfunction, identifying biomarkers of disease progression, and developing targeted therapies are essential for improving outcomes in this vulnerable population. Furthermore, global initiatives focused on enhancing access to prevention, testing, and treatment services are critical for reducing the burden of neonatal HIV infection and achieving long-term health equity.[20-22]

HIV Infection in Neonates

Human Immunodeficiency Virus (HIV) infection in neonates presents unique challenges due to the immaturity of their immune systems and the circumstances of vertical transmission from infected mothers. Neonates can acquire HIV during pregnancy, childbirth, or through breastfeeding, highlighting the critical importance of prevention strategies and early detection.

Despite global efforts to reduce mother-to-child transmission through antiretroviral therapy (ART) and other interventions, HIV infection in neonates remains a significant public health concern, particularly in regions with high prevalence rates.[23-27] Vertical transmission of HIV from mother to child accounts for the majority of pediatric HIV infections globally. Factors influencing transmission risk include maternal viral load, presence of co-infections (e.g., hepatitis B and C), breastfeeding practices, and access to prenatal care and ART. In the absence of preventive measures, the risk of transmission can be as high as 25-45%, underscoring the importance of universal testing and comprehensive maternal health interventions.[28-30] Upon exposure to HIV, neonatal immune responses differ from those of older children and adults due to immune system immaturity and the influence of maternal antibodies. HIV primarily targets CD4+ T lymphocytes, leading to their depletion and dysfunction. This depletion compromises the immune system's ability to mount effective responses against pathogens, increasing susceptibility to opportunistic infections. Furthermore, HIV disrupts the balance of cytokines and chemokines, promoting chronic immune activation and inflammation that further impairs immune function.[31-35]

Clinical manifestations of HIV in neonates can vary widely and may include failure to thrive, recurrent infections, hepatosplenomegaly, and neurodevelopmental delays. Diagnosis typically involves virological testing shortly after birth to detect HIV RNA or DNA, followed by confirmatory testing at later stages. Challenges in diagnosis include the need for specialized testing facilities, particularly in resource-limited settings, and the potential for false-negative results during the window period before HIV antibodies are detectable.[36-40] Preventing vertical transmission of HIV remains a cornerstone of pediatric HIV control efforts. Strategies include maternal ART initiation before conception or early in pregnancy, elective caesarean delivery in some cases, avoidance of breastfeeding where safe alternatives are available, and administration of antiretroviral prophylaxis to the neonate. These interventions aim to reduce maternal viral load, prevent exposure during childbirth, and minimize postnatal transmission risks.[41-45] Early initiation of ART in HIV-positive neonates is crucial for reducing viral replication, preserving immune function, and improving clinical outcomes. ART regimens for neonates are tailored based on factors such as age, weight, and potential drug interactions. Challenges in ART administration includes ensuring adherence to treatment protocols, managing drug resistance, and addressing potential long-term side effects. Monitoring of viral load and immune parameters is essential to assess treatment efficacy and guide adjustments.[46-50] While ART can effectively suppress viral replication, immune reconstitution in HIV-positive neonates may be incomplete, leading to persistent immune activation and inflammation. Long-term outcomes vary depending on the timing of ART initiation, adherence to treatment, presence of co-infections, and socio-economic factors. Studies suggest that early initiation of ART and effective management of immune dysregulation can improve survival rates and quality of life in HIV-positive neonates.[51-52]

Immune System Development in Neonates

The neonatal period represents a critical phase in immune system development, marked by a gradual transition from reliance on maternal immunity to the establishment of autonomous immune responses. This developmental process is essential for protecting neonates against infections encountered early in life and for establishing immune memory that persists into

adulthood.[53-54] During gestation, neonates acquire passive immunity through the transfer of maternal antibodies across the placenta. Maternal antibodies, primarily immunoglobulin G (IgG), provide protection against a wide range of pathogens during the early postnatal period. This passive transfer of immunity is critical for bolstering neonatal defenses until the infant's own immune system matures sufficiently to produce its antibodies.[55-56] Neonates possess a diverse array of immune cells, albeit in varying stages of maturation. Key immune cell populations include T lymphocytes (both CD4+ and CD8+ subsets), B lymphocytes, natural killer (NK) cells, dendritic cells, macrophages, and innate immune cells. Despite their presence, these cells exhibit functional immaturity compared to adult counterparts, influencing the neonate's ability to mount robust immune responses.[57-58] T lymphocytes play pivotal roles in orchestrating adaptive immune responses and generating immunological memory. In neonates, T cell development begins in the fetal thymus during gestation and continues postnatally. However, neonatal T cells are functionally immature, characterized by limited antigen-specific responses and reduced cytokine production. This immaturity contributes to increased susceptibility to infections and challenges in vaccine responsiveness early in life.[59-60]

B lymphocytes are responsible for antibody production and humoral immunity. Neonatal B cells undergo maturation in lymphoid tissues and bone marrow, gradually acquiring the ability to differentiate into plasma cells that secrete antibodies. However, neonatal B cells exhibit reduced diversity and affinity maturation compared to adult B cells, resulting in weaker and less specific antibody responses. Maternal antibodies acquired prenatally provide temporary protection until neonatal B cells can generate their antibody repertoire.[61-62] Innate immune responses serve as the first line of defense against infections in neonates. Innate immune cells, such as dendritic cells, macrophages, and NK cells, detect and respond to pathogens through pattern recognition receptors (PRRs). Despite their critical role in early immune defense, neonatal innate immune cells display functional immaturity, characterized by impaired cytokine production and antigen presentation. This immaturity contributes to reduced microbial clearance and prolonged inflammatory responses.[63-64] The immaturity of neonatal immune responses poses challenges for effective immune defense against pathogens. Neonates are particularly vulnerable to infections, including opportunistic pathogens, due to limited immune memory and functional deficits in key immune cell populations. Additionally, factors such as preterm birth, maternal health status, and environmental exposures can further compromise neonatal immune function, exacerbating susceptibility to infections.[65-66]

Impact of Infections on Neonatal Immunity

Infections, including HIV, can profoundly impact neonatal immune development and function. HIV infection in neonates disrupts immune cell homeostasis, leading to CD4+ T cell depletion, impaired cytokine regulation, and chronic immune activation. These alterations compromise the neonate's ability to mount effective immune responses and increase susceptibility to opportunistic infections. Understanding the specific effects of HIV on neonatal immune responses is essential for developing targeted interventions to mitigate immune dysregulation and improve clinical outcomes.[67-69] Strategies to enhance neonatal immune responses and mitigate vulnerabilities include optimizing maternal health during pregnancy, promoting breastfeeding where safe,

administering vaccinations according to recommended schedules, and early detection and treatment of infections. Research into immune modulation therapies, such as cytokine inhibitors and immune checkpoint blockade, holds promise for enhancing immune function in neonates and improving responses to infections, including HIV.[70--72]

Immune Dysregulation in HIV-Positive Neonates

Human Immunodeficiency Virus (HIV) infection in neonates disrupts immune homeostasis and leads to profound immune dysregulation, characterized by altered immune cell function, cytokine imbalances, and chronic inflammation. HIV primarily targets CD4+ T lymphocytes, crucial orchestrators of adaptive immune responses. In neonates, HIV infection leads to rapid depletion of CD4+ T cells, impairing the immune system's ability to mount effective responses against pathogens. The loss of CD4+ T cells is exacerbated by viral replication and immune activation, contributing to immunodeficiency and increased susceptibility to opportunistic infections. Additionally, HIV infection disrupts the balance of CD8+ T cells, which play roles in viral control and cytotoxic responses, further compromising immune function.[73-77] HIV infection in neonates induces dysregulation of cytokine networks, with elevated levels of pro-inflammatory cytokines such as interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and interleukin-1 beta (IL-1β). These cytokines drive chronic immune activation and inflammation, which are detrimental to immune cell function and tissue integrity. Conversely, there may be inadequate production of anti-inflammatory cytokines such as interleukin-10 (IL-10), impairing the resolution of inflammation and exacerbating immune dysregulation.[78-79] Innate immune responses in HIV-positive neonates are also affected, with alterations observed in dendritic cells, macrophages, and natural killer (NK) cells. HIV infection impairs innate immune cell function, reducing their capacity to detect and respond to pathogens effectively. Dysfunctional innate immunity contributes to prolonged viral persistence, chronic inflammation, and impaired immune surveillance, further complicating the clinical course of HIV infection in neonates.[80-81]

Chronic immune activation is a hallmark of HIV infection in neonates, driven by persistent viral replication and dysregulated immune responses. Elevated levels of immune activation markers, such as soluble CD14 and CD163, reflect ongoing immune activation and correlate with disease progression. Prolonged immune activation not only impairs immune function but also contributes to tissue damage, systemic inflammation, and increased susceptibility to co-infections.[82-83] Diagnosing and monitoring immune dysregulation in HIV-positive neonates pose significant challenges. Traditional biomarkers of HIV disease progression, such as CD4+ T cell counts and viral load measurements, may not fully capture the complexities of immune dysregulation in neonates. Biomarkers that reflect immune activation, inflammation, and immune cell function are needed to assess disease severity, guide therapeutic decisions, and monitor treatment responses effectively.[84-85] Beyond immunological consequences, immune dysregulation in HIV-positive neonates may impact neurodevelopmental outcomes. Chronic inflammation and immune activation have been linked to neurocognitive impairments and developmental delays in children with HIV. Early and sustained viral suppression with ART is critical for minimizing neurodevelopmental sequelae and optimizing long-term cognitive outcomes in affected neonates.[86-87] Early initiation of ART is essential for reducing viral replication, preserving immune

function, and improving clinical outcomes in HIV-positive neonates. ART regimens are tailored based on factors such as age, weight, viral resistance profiles, and co-infections. Despite the benefits of ART, challenges such as drug adherence, drug resistance, and long-term toxicity remain, necessitating ongoing research into safer and more effective treatment strategies for neonates.[88-89] Novel therapeutic approaches to modulate immune dysregulation in HIV-positive neonates are under investigation. These include immune modulators, cytokine inhibitors, therapeutic vaccines, and strategies to enhance immune reconstitution. Targeted interventions aimed at restoring immune balance and reducing chronic inflammation hold promise for improving immune function and clinical outcomes in this vulnerable population.[90]

Immune Cell Dysfunction

HIV primarily targets CD4+ T cells, leading to their depletion and dysfunction. In neonates, this depletion is particularly detrimental given their already limited T cell numbers. HIV infection impairs the ability of CD4+ T cells to provide help to other immune cells, leading to a weakened immune response. Additionally, the virus induces a state of chronic activation in T cells, which contributes to their exhaustion and apoptosis.[91] B cells, responsible for antibody production, also exhibit significant abnormalities in HIV-positive neonates. HIV infection can lead to polyclonal B cell activation, hypergammaglobulinemia, and impaired specific antibody responses. This dysfunction compromises the neonate's ability to produce effective antibodies against pathogens, increasing their susceptibility to infections. Immune cell dysfunction is a hallmark of HIV infection in neonates, profoundly impacting both innate and adaptive immune responses. Understanding the mechanisms underlying immune cell dysfunction is crucial for developing targeted interventions to mitigate the consequences of HIV infection in this vulnerable population.[92] Human Immunodeficiency Virus (HIV) targets CD4+ T lymphocytes, central players in orchestrating adaptive immune responses. In neonates, HIV infection leads to rapid and profound depletion of CD4+ T cells, impairing the immune system's ability to mount effective immune responses against pathogens. The loss of CD4+ T cells compromise immune surveillance, disrupts immune homeostasis, and predisposes neonates to opportunistic infections. CD4+ T cell depletion is a critical factor in HIV disease progression and remains a major focus of therapeutic interventions aimed at preserving immune function.[93] CD8+ T cells play a crucial role in cytotoxic responses and controlling viral infections. In HIV-positive neonates, CD8+ T cell function may be impaired due to chronic immune activation and exhaustion. HIV-specific CD8+ T cells exhibit reduced cytotoxic activity and proliferative capacity, limiting their ability to suppress viral replication effectively. Dysfunctional CD8+ T cell responses contribute to viral persistence and may compromise immune surveillance against opportunistic infections, highlighting the importance of restoring CD8+ T cell function in therapeutic strategies.[94]

B lymphocytes are responsible for antibody production and humoral immunity. In HIV-infected neonates, B cell development and function are impaired, contributing to deficiencies in antibody production and impaired immune responses to pathogens. HIV-induced immune activation and inflammation can lead to polyclonal B cell activation and hypergammaglobulinemia, but specific antibody responses against pathogens may be compromised. Strategies to restore B cell function and enhance antibody production are critical for improving immune defense in HIV-positive

neonates.[95] Innate immune cells, including dendritic cells, macrophages, and natural killer (NK) cells, play essential roles in detecting and responding to pathogens. HIV infection in neonates disrupts innate immune cell function, impairing their ability to initiate and coordinate immune responses. Dysfunctional dendritic cells and macrophages may fail to effectively present antigens and activate T cells, while compromised NK cell function diminishes their cytotoxic activity against infected cells. Restoring innate immune cell function is crucial for enhancing early immune responses and controlling viral replication in HIV-positive neonates.[96]

Impact on Immune Activation and Inflammation

Chronic immune activation and inflammation are characteristic features of HIV infection in neonates, driven by persistent viral replication and dysregulated immune responses. Elevated levels of pro-inflammatory cytokines, such as interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and interferon-gamma (IFN-γ), contribute to systemic inflammation and immune cell dysfunction. Prolonged immune activation not only impairs immune function but also leads to tissue damage and increased susceptibility to co-infections. Strategies aimed at attenuating chronic inflammation and restoring immune balance are critical for improving clinical outcomes in HIV-positive neonates.[97] Despite advances in antiretroviral therapy (ART), achieving immune reconstitution in HIV-positive neonates remains challenging. Early initiation of ART is essential for suppressing viral replication and preserving immune function, but ART alone may not fully restore CD4+ T cell counts or normalize immune activation. Persistent immune dysregulation, residual viral reservoirs, and potential long-term effects of early HIV exposure on immune development necessitate ongoing research into novel therapeutic approaches to enhance immune reconstitution and improve long-term health outcomes.[98] Cytokines play a pivotal role in immune regulation and are essential for coordinating responses to infections and maintaining immune homeostasis. In HIV-positive neonates, dysregulation of cytokine networks contributes significantly to immune dysfunction, chronic inflammation, and disease progression.[99]

HIV infection in neonates stimulates the production of pro-inflammatory cytokines, including interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), and interleukin-12 (IL-12). These cytokines are produced primarily by immune cells such as macrophages, dendritic cells, and T lymphocytes in response to viral replication and immune activation. Elevated levels of pro-inflammatory cytokines contribute to systemic inflammation, immune cell activation, and tissue damage, exacerbating immune dysfunction and increasing susceptibility to opportunistic infections.[100] In contrast to pro-inflammatory cytokines, anti-inflammatory cytokines such as interleukin-10 (IL-10) play a critical role in regulating immune responses and mitigating excessive inflammation. HIV infection in neonates may disrupt the balance between pro-inflammatory and anti-inflammatory cytokines, resulting in inadequate production of IL-10 and impaired resolution of inflammation. Deficiencies in IL-10-mediated regulatory mechanisms contribute to sustained immune activation, tissue pathology, and immune dysregulation observed in HIV-positive neonates.[101] HIV infection in neonates can alter the balance between T helper 1 (Th1) and T helper 2 (Th2) cytokine responses. Th1 cytokines, such as interferon-gamma (IFN-γ) and interleukin-2 (IL-2), are essential for cellular immunity and activating macrophages to combat intracellular pathogens. In contrast, Th2 cytokines, including

interleukin-4 (IL-4) and interleukin-10 (IL-10), promote humoral immunity and allergic responses. Imbalances favoring Th2 cytokine profiles may impair cellular immune responses against HIV and opportunistic infections, contributing to disease progression and immune dysfunction.[102] Chemokines are a family of small cytokines that mediate leukocyte trafficking and recruitment to sites of inflammation or infection. HIV infection in neonates dysregulates chemokine production, altering immune cell migration patterns and inflammatory responses. Elevated levels of chemokines, such as CCL2 (MCP-1) and CXCL10 (IP-10), contribute to immune cell activation, tissue inflammation, and recruitment of HIV target cells to infected tissues. Dysregulated chemokine signaling further exacerbates immune dysregulation and complicates efforts to control viral replication in HIV-positive neonates.

Impact on Immune Activation and Pathogenesis

Cytokine imbalances in HIV-positive neonates contribute to sustained immune activation and chronic inflammation, which are central features of HIV pathogenesis. Persistent immune activation leads to depletion of CD4+ T cells, dysfunction of antigen-presenting cells, and impaired cytotoxic T cell responses. Moreover, chronic inflammation promotes microbial translocation, exacerbates tissue damage, and increases the risk of co-infections and non-AIDS-related complications. Strategies aimed at modulating cytokine imbalances and attenuating immune activation are critical for improving immune function and reducing disease progression in HIV-positive neonates.[103] Targeting cytokine imbalances represents a promising therapeutic approach to mitigate immune dysregulation in HIV-positive neonates. Strategies include cytokine inhibitors to suppress pro-inflammatory cytokine production, cytokine replacement therapies to restore immune regulatory pathways, and immune modulators to enhance anti-inflammatory responses. Combination therapies that target multiple cytokine pathways may be necessary to achieve optimal immune modulation and improve clinical outcomes in this vulnerable population.

Effects of Antiretroviral Therapy (ART)

Antiretroviral therapy (ART) has revolutionized the management of HIV infection, including its profound impact on immune function and overall health outcomes in both adults and children, including neonates. ART exerts potent effects on HIV replication, leading to rapid suppression of viral load and restoration of CD4+ T cell counts. In neonates, early initiation of ART is critical for preserving immune function and preventing immune cell depletion caused by HIV infection. ART targets viral enzymes, such as reverse transcriptase and protease, inhibiting viral replication at multiple stages of the viral life cycle. By reducing viral burden, ART helps to preserve immune system integrity, enhance immune reconstitution, and mitigate the risk of opportunistic infections. ART-mediated suppression of viral replication allows for gradual restoration of immune responses in HIV-positive neonates. Over time, ART enables recovery of CD4+ T cell counts, improves CD4+/CD8+ T cell ratios, and enhances T cell function. Restored immune function contributes to better control of opportunistic infections and reduces the frequency of immune-mediated complications. Early initiation of ART is associated with more robust immune reconstitution and improved long-term outcomes, underscoring the importance of timely diagnosis and treatment initiation in neonates.[100]

Reduction in Immune Activation and Inflammation

Chronic immune activation and inflammation are hallmarks of untreated HIV infection, contributing to progressive immune dysfunction and disease progression. ART suppresses viral replication, thereby reducing antigenic stimulation and immune activation. As a result, ART helps to dampen systemic inflammation, normalize cytokine profiles, and mitigate immune-mediated tissue damage. Reduced immune activation contributes to improved immune function, decreases the risk of non-AIDS-related complications, and promotes overall health restoration in HIV-positive neonates. Beyond immunological benefits, early initiation of ART in neonates may mitigate the neurodevelopmental consequences associated with HIV infection. HIV-associated neurocognitive impairments and developmental delays are linked to viral replication in the central nervous system and chronic inflammation. ART-mediated viral suppression in the early stages of infection may prevent neuronal injury, preserve cognitive function, and improve neurodevelopmental outcomes in affected neonates. Optimal neurodevelopmental monitoring and early intervention strategies are essential components of comprehensive HIV care in neonates. Despite its profound benefits, ART in neonates presents unique challenges and considerations. These include the need for pediatric formulations with appropriate dosing and safety profiles, adherence to complex treatment regimens, potential drug interactions, and long-term effects on growth and development. Additionally, barriers to healthcare access and resource limitations in low- and middle-income countries pose challenges to timely diagnosis and ART initiation in neonates born to HIV-positive mothers.[101]

Potential Therapeutic Strategies

HIV infection in neonates presents unique challenges due to the immaturity of their immune systems and the rapid progression of disease without intervention. While antiretroviral therapy (ART) remains the cornerstone of treatment, emerging therapeutic strategies aim to complement ART or address specific aspects of immune dysregulation and viral persistence. Here are potential therapeutic approaches under investigation for improving outcomes in HIV-positive neonates: Early initiation of ART in neonates is critical for achieving rapid viral suppression, preserving immune function, and reducing the establishment of viral reservoirs. Optimizing ART regimens involves selecting combinations that are potent, well-tolerated, and suitable for neonatal dosing. Advances in pediatric pharmacology aim to develop age-appropriate formulations and dosing schedules to enhance treatment adherence and minimize side effects. Immunomodulatory therapies seek to modulate immune responses to achieve better control of HIV infection and reduce immune activation. Strategies include immune checkpoint inhibitors, which target pathways involved in immune exhaustion and enhance T cell responses. Additionally, cytokine inhibitors may be used to dampen excessive inflammation and restore immune balance, potentially improving immune function and reducing long-term complications. Therapeutic vaccination strategies aim to boost immune responses against HIV antigens and enhance immune surveillance. While preventive vaccines for HIV are still under development, therapeutic vaccines in neonates focus on enhancing immune recognition and targeting viral reservoirs. Approaches include viral vector-based vaccines, DNA vaccines, and peptide vaccines designed to elicit robust T cell and antibody responses against HIV-specific antigens.[102]

Gene therapy and gene editing technologies offer innovative approaches to combat HIV infection by modifying host cells or viral DNA. In neonates, gene therapy may involve the delivery of engineered cells with enhanced resistance to HIV infection or modification of hematopoietic stem cells to produce HIV-resistant immune cells. CRISPR/Cas9 gene editing holds promise for directly targeting viral DNA in infected cells, potentially achieving functional cure or sustained remission from HIV. Broadly neutralizing antibodies (bNAbs) are potent antibodies that target conserved regions of the HIV envelope glycoprotein, preventing viral entry into host cells. In neonates, bNAbs may be administered passively to provide immediate protection against HIV and reduce viral load. Ongoing research focuses on developing long-acting bNAbs and evaluating their efficacy in preventing mother-to-child transmission and controlling HIV replication in neonates. Combination therapies integrate multiple therapeutic approaches to enhance treatment efficacy and address different aspects of HIV pathogenesis simultaneously. For example, combining ART with immunomodulatory therapies or therapeutic vaccines may synergistically improve viral control, reduce immune activation, and promote immune reconstitution in HIV-positive neonates. Tailored combination strategies aim to achieve sustained virologic suppression and long-term immune restoration while minimizing treatment-related complications. Supportive care plays a crucial role in optimizing outcomes for HIV-positive neonates by addressing nutritional deficiencies, managing co-infections, and promoting overall health and development. Nutritional interventions, including micronutrient supplementation and breastfeeding support where safe, contribute to immune health and may complement antiretroviral treatment in enhancing immune function and reducing morbidity.[103]

Conclusion

Addressing immune dysregulation in HIV-positive neonates represents a complex yet crucial endeavor in pediatric HIV care. HIV infection profoundly impacts immune function from the earliest stages of life, necessitating comprehensive strategies to mitigate immune dysregulation, optimize treatment outcomes, and improve long-term health prospects for affected neonates. The immune system of neonates is uniquely vulnerable, characterized by immaturity in both innate and adaptive immune responses. HIV infection exacerbates this vulnerability by targeting key immune cells, such as CD4+ T lymphocytes, and disrupting cytokine networks essential for immune regulation. This dysregulation leads to chronic inflammation, immune activation, and increased susceptibility to opportunistic infections, highlighting the urgent need for therapeutic interventions tailored to the specific challenges faced by HIV-positive neonates. Antiretroviral therapy (ART) remains the cornerstone of treatment, providing potent viral suppression, preserving immune function, and reducing morbidity and mortality. Early initiation of ART in neonates is critical for achieving optimal outcomes, including immune reconstitution and prevention of long-term complications associated with HIV infection. However, challenges such as drug adherence, drug resistance, and potential long-term effects of early HIV exposure on immune development underscore the importance of ongoing research and innovation in pediatric HIV care.

References

1. Yu JC, Khodadadi H, Malik A, Davidson B, Salles ÉD, Bhatia J, Hale VL, Baban B. Innate immunity of neonates and infants. Frontiers in immunology. 2018; 9:1759.

2. Goenka A, Kollmann TR. Development of immunity in early life. Journal of Infection. 2015;71: S112-120.
3. Lewis DB, Weitkamp JH, Levy O. Developmental immunology and role of host defenses in fetal and neonatal susceptibility to infection. In Remington and Klein's Infectious Diseases of the Fetus and Newborn Infant 2025: 73-159. Elsevier.
4. Obeagu EI, Anyiam AF, Obeagu GU. Managing Anemia in HIV through Blood Transfusions: Clinical Considerations and Innovations. Elite Journal of HIV, 2024; 2(1): 16-30
5. Obeagu EI, Obeagu, GU. Counting Cells, Shaping Fates: CD4/CD8 Ratios in HIV. Elite Journal of Scientific Research and Review, 2024; 2(1): 37-50
6. Obeagu EI, Obeagu GU. Eosinophil Dynamics in Pregnancy among Women Living with HIV: A Comprehensive Review. Int. J. Curr. Res. Med. Sci. 2024;10(1):11-24.
7. Obeagu EI, Obeagu GU, Hauwa BA, Umar AI. Neutrophil Dynamics: Unveiling Their Role in HIV Progression within Malaria Patients. Journal home page: http://www. journalijiar. com.;12(01).
8. Obeagu EI, Obeagu, GU. P-Selectin and Platelet Activation in HIV: Implications for Antiviral Therapy. Elite Journal of Scientific Research and Review, 2024; 2(1): 17-41
9. Obeagu EI, Obeagu GU. The Intricate Relationship Between Erythropoietin and HIV-Induced Anemia: Unraveling Pathways for Therapeutic Insights. Int. J. Curr. Res. Chem. Pharm. Sci. 2024;11(2):30-40.
10. Obeagu EI, Anyiam AF, Obeagu GU. Erythropoietin Therapy in HIV-Infected Individuals: A Critical Review. Elite Journal of HIV, 2024; 2(1): 51-64
11. Obeagu EI, Obeagu GU. Strength in Unity: Building Support Networks for HIV Patients in Uganda. Elite Journal of Medicine, 2024; 2(1): 1-16
12. Obeagu EI, Obeagu GU. Eosinophilic Changes in Placental Tissues of HIV-Positive Pregnant Women: A Review. Elite Journal of Laboratory Medicine, 2024; 2(1): 14-32
13. Kuhn L, Meddows-Taylor S, Gray G, Tiemessen C. Human immunodeficiency virus (HIV)–specific cellular immune responses in newborns exposed to HIV in utero. Clinical infectious diseases. 2002;34(2):267-276.
14. Muenchhoff M, Prendergast AJ, Goulder PJ. Immunity to HIV in early life. Frontiers in immunology. 2014; 5:391.
15. Geng ST, Zhang ZY, Wang YX, Lu D, Yu J, Zhang JB, Kuang YQ, Wang KH. Regulation of gut microbiota on immune reconstitution in patients with acquired immunodeficiency syndrome. Frontiers in microbiology. 2020; 11:594820.
16. Obeagu EI, Obeagu, GU. The Crucial Role of Erythropoietin in Managing Anemia in HIV: A Review. Elite Journal of Scientific Research and Review, 2024; 2(1): 24-36
17. Obeagu EI, Ubosi NI, Obeagu GU, Obeagu AA. Nutritional Strategies for Enhancing Immune Resilience in HIV: A Review. Int. J. Curr. Res. Chem. Pharm. Sci. 2024;11(2):41-51.
18. Obeagu EI, Obeagu GU. Assessing Platelet Functionality in HIV Patients Receiving Antiretroviral Therapy: Implications for Risk Assessment. Elite Journal of HIV, 2024; 2(3): 14-26

19. Obeagu EI, Elamin EAI Obeagu GU. Understanding the Intersection of Highly Active Antiretroviral Therapy and Platelets in HIV Patients: A Review. Elite Journal of Haematology, 2024; 2(3): 111-117
20. Obeagu EI, Obeagu GU. Understanding ART and Platelet Functionality: Implications for HIV Patients. Elite Journal of HIV, 2024; 2(2): 60-73
21. Obeagu EI, Obeagu GU. Neonatal Outcomes in Children Born to Mothers with Severe Malaria, HIV, and Transfusion History: A Review. Elite Journal of Nursing and Health Science, 2024; 2(3): 38-58
22. Obeagu EI. Erythropoietin and the Immune System: Relevance in HIV Management. Elite Journal of Health Science, 2024; 2(3): 23-35
23. Obeagu EI, Obeagu GU. Understanding Immune Cell Trafficking in Tuberculosis-HIV Coinfection: The Role of L-selectin Pathways. Elite Journal of Immunology, 2024; 2(2): 43-59
24. Obeagu EI, Obeagu GU. Anemia and Erythropoietin: Key Players in HIV Disease Progression. Elite Journal of Haematology, 2024; 2(3): 42-57
25. Obeagu EI, Ayogu EE, Obeagu GU. Impact on Viral Load Dynamics: Understanding the Interplay between Blood Transfusion and Antiretroviral Therapy in HIV Management. Elite Journal of Nursing and Health Science, 2024; 2(2): 5-15
26. Obeagu EI, Obeagu GU. Immune Modulation in HIV-Positive Neonates: Insights and Implications for Clinical Management. Elite Journal of Nursing and Health Science, 2024; 2(3): 59-72
27. Ifeanyi OE, Obeagu GU. The values of prothrombin time among HIV positive patients in FMC owerri. International Journal of Current Microbiology and Applied Sciences. 2015;4(4):911-916. https://www.academia.edu/download/38320140/Obeagu_Emmanuel_Ifeanyi_and_Obeagu__Getrude_Uzoma2.EMMA1.pdf.
28. Yu JC, Khodadadi H, Malik A, Davidson B, Salles ÉD, Bhatia J, Hale VL, Baban B. Innate immunity of neonates and infants. Frontiers in immunology. 2018; 9:1759.
29. Levy O. Innate immunity of the newborn: basic mechanisms and clinical correlates. Nature Reviews Immunology. 2007;7(5):379-390.
30. Pieren DK, Boer MC, de Wit J. The adaptive immune system in early life: The shift makes it count. Frontiers in immunology. 2022; 13:1031924.
31. Rackaityte E, Halkias J. Mechanisms of fetal T cell tolerance and immune regulation. Frontiers in immunology. 2020; 11:588.
32. Sereme Y, Toumi E, Saifi E, Faury H, Skurnik D. Maternal immune factors involved in the prevention or facilitation of neonatal bacterial infections. Cellular Immunology. 2024; 395:104796.
33. Zhang X, Zhivaki D, Lo-Man R. Unique aspects of the perinatal immune system. Nature Reviews Immunology. 2017;17(8):495-507.
34. Sanidad KZ, Zeng MY. Neonatal gut microbiome and immunity. Current opinion in microbiology. 2020; 56:30-37.
35. Izuchukwu IF, Ozims SJ, Agu GC, Obeagu EI, Onu I, Amah H, Nwosu DC, Nwanjo HU, Edward A, Arunsi MO. Knowledge of preventive measures and management of HIV/AIDS

victims among parents in Umuna Orlu community of Imo state Nigeria. Int. J. Adv. Res. Biol. Sci. 2016;3(10): 55-65.DOI; 10.22192/ijarbs.2016.03.10.009

36. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. IOSR J Pharm Biol Sci. 2017;12(4):70-75. links/5988ab6d0f7e9b6c8539f73d/HIV-and-TB-co-infection-among-patients-who-used-Directly-Observed-Treatment-Short-course-centres-in-Yenagoa-Nigeria.pdf
37. Oloro OH, Oke TO, Obeagu EI. Evaluation of Coagulation Profile Patients with Pulmonary Tuberculosis and Human Immunodeficiency Virus in Owo, Ondo State, Nigeria. Madonna University journal of Medicine and Health Sciences. 2022;2(3):110-119.
38. Nwosu DC, Obeagu EI, Nkwocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Elendu HN, Ofoedeme CN, Ozims SJ, Nwankpa P. Change in Lipid Peroxidation Marker (MDA) and Non enzymatic Antioxidants (VIT C & E) in HIV Seropositive Children in an Urban Community of Abia State. Nigeria. J. Bio. Innov. 2016;5(1):24-30. links/5ae735e9a6fdcc5b33eb8d6a/CHANGE-IN-LIPID-PEROXIDATION-MARKER-MDAAND-NON-ENZYMATIC-ANTIOXIDANTS-VIT-C-E-IN-HIV-SEROPOSITIVE-CHILDREN-IN-AN-URBAN-COMMUNITY-OF-ABIA-STATE-NIGERIA.pdf.
39. Ifeanyi OE, Obeagu GU, Ijeoma FO, Chioma UI. The values of activated partial thromboplastin time (APTT) among HIV positive patients in FMC Owerri. Int J Curr Res Aca Rev. 2015; 3:139-144. https://www.academia.edu/download/38320159/Obeagu_Emmanuel_Ifeanyi3__et_al.IJCRAR.pdf.
40. Obiomah CF, Obeagu EI, Ochei KC, Swem CA, Amachukwu BO. Hematological indices o HIV seropositive subjects in Nnamdi Azikiwe University teaching hospital (NAUTH), Nnewi. Ann Clin Lab Res. 2018;6(1):1-4. links/5aa2bb17a6fdccd544b7526e/Haematological-Indices-of-HIV-Seropositive-Subjects-at-Nnamdi-Azikiwe.pdf
41. Omo-Emmanuel UK, Ochei KC, Osuala EO, Obeagu EI, Onwuasoanya UF. Impact of prevention of mother to child transmission (PMTCT) of HIV on positivity rate in Kafanchan, Nigeria. Int. J. Curr. Res. Med. Sci. 2017;3(2): 28-34.DOI: 10.22192/ijcrms.2017.03.02.005
42. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in Pakistan: Challenges and future recommendations at hand. Health Science Reports. 2023;6(8):e1450.
43. Obeagu EI, Amekpor F, Scott GY. An update of human immunodeficiency virus infection: Bleeding disorders. J Pub Health Nutri. 2023; 6 (1). 2023;139. links/645b4a6c2edb8e5f094d9bd9/An-update-of-human-immunodeficiency-virus-infection-Bleeding.pdf.
44. Obeagu EI, Scott GY, Amekpor F, Ofodile AC, Edoho SH, Ahamefula C. Prevention of New Cases of Human Immunodeficiency Virus: Pragmatic Approaches of Saving Life in Developing Countries. Madonna University journal of Medicine and Health Sciences. 2022;2(3):128-134. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/86.

45. Walter O, Anaebo QB, Obeagu EI, Okoroiwu IL. Evaluation of Activated Partial Thromboplastin Time and Prothrombin Time in HIV and TB Patients in Owerri Metropolis. Journal of Pharmaceutical Research International. 2022:29-34.
46. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng EU, Ikpeme M, Bassey JO, Paul AO. Cascade variabilities in TB case finding among people living with HIV and the use of IPT: assessment in three levels of care in cross River State, Nigeria. Journal of Pharmaceutical Research International. 2020;32(24):9-18.
47. Obeagu EI, Obeagu GU. A Review of knowledge, attitudes and socio-demographic factors associated with non-adherence to antiretroviral therapy among people living with HIV/AIDS. Int. J. Adv. Res. Biol. Sci. 2023;10(9):135-142.DOI: 10.22192/ijarbs.2023.10.09.015 links/6516faa61e2386049de5e828/A-Review-of-knowledge-attitudes-and-socio-demographic-factors-associated-with-non-adherence-to-antiretroviral-therapy-among-people-living-with-HIV-AIDS.pdf
48. Obeagu EI, Onuoha EC. Tuberculosis among HIV Patients: A review of Prevalence and Associated Factors. Int. J. Adv. Res. Biol. Sci. 2023;10(9):128-134.DOI: 10.22192/ijarbs.2023.10.09.014 links/6516f938b0df2f20a2f8b0e0/Tuberculosis-among-HIV-Patients-A-review-of-Prevalence-and-Associated-Factors.pdf.
49. Obeagu EI, Ibeh NC, Nwobodo HA, Ochei KC, Iwegbulam CP. Haematological indices of malaria patients coinfected with HIV in Umuahia. Int. J. Curr. Res. Med. Sci. 2017;3(5):100-104.DOI: 10.22192/ijcrms.2017.03.05.014 https://www.academia.edu/download/54317126/Haematological_indices_of_malaria_patients_coinfected_with_HIV.pdf
50. Okorie HM, Obeagu Emmanuel I, Okpoli Henry CH, Chukwu Stella N. Comparative study of enzyme linked immunosorbent assay (Elisa) and rapid test screening methods on HIV, Hbsag, Hcv and Syphilis among voluntary donors in. Owerri, Nigeria. J Clin Commun Med. 2020;2(3):180-183.DOI: **DOI:** 10.32474/JCCM.2020.02.000137 links/5f344530458515b7291bd95f/Comparative-Study-of-Enzyme-Linked-Immunosorbent-Assay-ElISA-and-Rapid-Test-Screening-Methods-on-HIV-HBsAg-HCV-and-Syphilis-among-Voluntary-Donors-in-Owerri-Nigeria.pdf.
51. Emannuel G, Martin O, Peter OS, Obeagu EI, Daniel K. Factors Influencing Early Neonatal Adverse Outcomes among Women with HIV with Post Dated Pregnancies Delivering at Kampala International University Teaching Hospital, Uganda. Asian Journal of Pregnancy and Childbirth. 2023 Jul 29;6(1):203-211. http://research.sdpublishers.net/id/eprint/2819/.
52. Vincent CC, Obeagu EI, Agu IS, Ukeagu NC, Onyekachi-Chigbu AC. Adherence to Antiretroviral Therapy among HIV/AIDS in Federal Medical Centre, Owerri. Journal of Pharmaceutical Research International. 2021;33(57A):360-368.
53. Madekwe CC, Madekwe CC, Obeagu EI. Inequality of monitoring in Human Immunodeficiency Virus, Tuberculosis and Malaria: A Review. Madonna University journal of Medicine and Health Sciences. 2022;2(3):6-15. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/69
54. Echendu GE, Vincent CC, Ibebuike J, Asodike M, Naze N, Chinedu EP, Ohale B, Obeagu EI. WEIGHTS OF INFANTS BORN TO HIV INFECTED MOTHERS: A

PROSPECTIVE COHORT STUDY IN FEDERAL MEDICAL CENTRE, OWERRI, IMO STATE. European Journal of Pharmaceutical and Medical Research, 2023; 10(8): 564-568
55. Wilson EM, Sereti I. Immune restoration after antiretroviral therapy: the pitfalls of hasty or incomplete repairs. Immunological reviews. 2013;254(1):343-354.
56. Misgena DK. The pattern of immunologic and virologic responses to Highly Active Antiretroviral Treatment (HAART): Does success bring further challenges? Ethiopian Journal of Health Development. 2011;25(1):61-70.
57. Davenport MP, Khoury DS, Cromer D, Lewin SR, Kelleher AD, Kent SJ. Functional cure of HIV: the scale of the challenge. Nature Reviews Immunology. 2019;19(1):45-54.
58. Geretti AM, Brook G, Cameron C, Chadwick D, French N, Heyderman R, Ho A, Hunter M, Ladhani S, Lawton M, MacMahon E. British HIV Association guidelines on the use of vaccines in HIV-positive adults 2015. HIV medicine. 2016;17(53):S2-81.
59. Laupèze B, Del Giudice G, Doherty MT, Van der Most R. Vaccination as a preventative measure contributing to immune fitness. npj Vaccines. 2021;6(1):93.
60. Obeagu EI, Obeagu GU. Immunological Aspects of HIV Control in Perinatally Infected Infants: A Review**.** Elite Journal of Immunology, 2024; 2(6): 1-14
61. Obeagu EI, Obeagu GU. An update on Early Immunological Markers in HIV-Exposed Infants**.** Elite Journal of Immunology, 2024; 2(6): 15-25
62. Obeagu EI. Markers of Immune Activation in HIV-Exposed Infants. Elite Journal of Health Science, 2024; 2(6): 1-14
63. Obeagu EI, Obarezi TN, Omeh YN, Okoro NK, Eze OB. Assessment of some haematological and biochemical parametrs in HIV patients before receiving treatment in Aba, Abia State, Nigeria. Res J Pharma Biol Chem Sci. 2014; 5:825-830.
64. Obeagu EI, Obarezi TN, Ogbuabor BN, Anaebo QB, Eze GC. Pattern of total white blood cell and differential count values in HIV positive patients receiving treatment in Federal Teaching Hospital Abakaliki, Ebonyi State, Nigeria. International Journal of Life Science, Biotechnology and Pharama Research. 2014; 391:186-189.
65. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. Madonna University journal of Medicine and Health Sciences. 2023; 3 (1): 7-12.
66. Oloro OH, Obeagu EI. A Systematic Review on Some Coagulation Profile in HIV Infection. International Journal of Innovative and Applied Research. 2022;10(5):1-11.
67. Nwosu DC, Obeagu EI, Nkwuocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Ezemma MC, Okpomeshine EA, Ozims SJ, Agu GC. Alterations in superoxide dismutiase, vitamins C and E in HIV infected children in Umuahia, Abia state. International Journal of Advanced Research in Biological Sciences. 2015;2(11):268-271.
68. Nwovu AI, Ifeanyi OE, Uzoma OG, Nwebonyi NS. Occurrence of Some Blood Borne Viral Infection and Adherence to Universal Precautions among Laboratory Staff in Federal Teaching Hospital Abakaliki Ebonyi State. Arch Blood Transfus Disord. 2018;1(2).
69. Obeagu EI, Obeagu GU, Ede MO, Odo EO, Buhari HA. Translation of HIV/AIDS knowledge into behavior change among secondary school adolescents in Uganda: A review. Medicine (Baltimore). 2023;102(49): e36599. doi: 10.1097/MD.0000000000036599. PMID: 38065920; PMCID: PMC10713174.

70. Anyiam AF, Arinze-Anyiam OC, Irondi EA, Obeagu EI. Distribution of ABO and rhesus blood grouping with HIV infection among blood donors in Ekiti State Nigeria. Medicine (Baltimore). 2023;102(47): e36342. doi: 10.1097/MD.0000000000036342. PMID: 38013335; PMCID: PMC10681551.
71. Echefu SN, Udosen JE, Akwiwu EC, Akpotuzor JO, Obeagu EI. Effect of Dolutegravir regimen against other regimens on some hematological parameters, CD4 count and viral load of people living with HIV infection in South Eastern Nigeria. Medicine (Baltimore). 2023;102(47): e35910. doi: 10.1097/MD.0000000000035910. PMID: 38013350; PMCID: PMC10681510.
72. Opeyemi AA, Obeagu EI. Regulations of malaria in children with human immunodeficiency virus infection: A review. Medicine (Baltimore). 2023;102(46): e36166. doi: 10.1097/MD.0000000000036166. PMID: 37986340; PMCID: PMC10659731.
73. Obeagu EI, Ubosi NI, Uzoma G. Storms and Struggles: Managing HIV Amid Natural Disasters. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(11):14-25.
74. Obeagu EI, Obeagu GU. Human Immunodeficiency Virus and tuberculosis infection: A review of prevalence of associated factors. Int. J. Adv. Multidiscip. Res. 2023;10(10):56-62.
75. Obeagu EI, Obeagu GU. Unmasking the Truth: Addressing Stigma in the Fight Against HIV. Elite Journal of Public Health. 2024;2(1):8-22.
76. Obeagu EI, Obeagu GU, Okwuanaso CB. Optimizing Immune Health in HIV Patients through Nutrition: A Review. Elite Journal of Immunology. 2024;2(1):14-33.
77. Obeagu EI, Obeagu GU. Utilization of immunological ratios in HIV: Implications for monitoring and therapeutic strategies. Medicine. 2024;103(9): e37354.
78. Obeagu EI, Obeagu GU. CD8 Dynamics in HIV Infection: A Synoptic Review. Elite Journal of Immunology. 2024;2(1):1-3.
79. Obeagu EI, Obeagu GU. Implications of B Lymphocyte Dysfunction in HIV/AIDS. Elite Journal of Immunology. 2024;2(1):34-46.
80. Obeagu EI, Obeagu GU. Maternal Influence on Infant Immunological Responses to HIV: A Review. Elite Journal of Laboratory Medicine. 2024;2(1):46-58.
81. Obeagu EI, Obeagu GU. Understanding B Lymphocyte Functions in HIV Infection: Implications for Immune Dysfunction and Therapeutic Strategies. Elite Journal of Medicine. 2024;2(1):35-46.
82. Obeagu EI, Obeagu GU. Platelet-Driven Modulation of HIV: Unraveling Interactions and Implications. Journal home page: http://www. journalijiar. com.;12(01).
83. Obeagu EI, Anyiam AF, Obeagu GU. Managing Hematological Complications in HIV: Erythropoietin Considerations. Elite Journal of HIV. 2024;2(1):65-78.
84. Obeagu EI, Obeagu GU, Hauwa BA, Umar AI. Hematocrit Variations in HIV Patients Co-infected with Malaria: A Comprehensive Review. Journal home page: http://www. journalijiar. com.;12(01).
85. Obeagu EI, Obeagu GU. Synergistic Effects of Blood Transfusion and HIV in Children Under 5 Years with Severe Malaria: A Review. Elite Journal of HIV. 2024;2(1):31-50.
86. Obeagu EI, Anyiam AF, Obeagu GU. Unveiling B Cell Mediated Immunity in HIV Infection: Insights, Challenges, and Potential Therapeutic Avenues. Elite Journal of HIV. 2024;2(1):1-5.

87. Obeagu EI, Obeagu GU. Hematocrit Fluctuations in HIV Patients Co-infected with Malaria Parasites: A Comprehensive Review. Int. J. Curr. Res. Med. Sci. 2024;10(1):25-36.
88. Obeagu EI, Obeagu GU. Transfusion Therapy in HIV: Risk Mitigation and Benefits for Improved Patient Outcomes. Sciences. 2024;4(1):32-37.
89. Obeagu EI, Obeagu GU. Mental Health and Psychosocial Effects of natural disaster on HIV Patients. Sciences. 2024;4(1):38-44.
90. Obeagu EI, Obeagu GU. Eosinophil-Associated Changes in Neonatal Thymic T Regulatory Cell Populations in HIV-Infected Pregnancies. Elite Journal of Health Science. 2024;2(1):33-42.
91. Obeagu EI, Obeagu GU. Advances in Understanding the Impact of Blood Transfusion on Anemia Resolution in HIV-Positive Children with Severe Malaria: A Comprehensive Review. Elite Journal of Haematology. 2024;2(1):26-41.
92. Obeagu EI, Ayogu EE, Obeagu GU. Interactions between Blood Transfusion and Antiretroviral Medications: Implications for Patient Care. Elite Journal of Medicine. 2024;2(2):104-115.
93. Obeagu EI, Obeagu GU. Maternal Eosinophilic Responses in HIV-Positive Pregnant Women: Unraveling Immunological Dynamics for Improved Maternal-Fetal Health. Elite Journal of Immunology. 2024;2(1):47-64.
94. Obeagu EI, Anyanwu CN, Obeagu GU. Challenges and Considerations in Managing Blood Transfusion for Individuals with HIV. Elite Journal of HIV. 2024;2(2):1-7.
95. Obeagu EI, Ubosi NI, Obeagu GU, Akram M. Early Infant Diagnosis: Key to Breaking the Chain of HIV Transmission. Elite Journal of Public Health. 2024;2(1):52-61.
96. Obeagu EI, Obeagu GU. Understanding Hematocrit Fluctuations in HIV-Malaria Coinfection for Improved Management. Elite Journal of Public Health. 2024;2(1):22-34.
97. Obeagu EI, Obeagu GU. The Impact of Erythropoietin on Preeclampsia in HIV-Positive Women: A Review. Elite Journal of Nursing and Health Science. 2024;2(1):21-31.
98. Obeagu EI, Obeagu GU. Platelet Distribution Width (PDW) as a Prognostic Marker for Anemia Severity in HIV Patients: A Comprehensive Review. Journal home page: http://www. journalijiar. com.;12(01).
99. Obeagu EI, Obeagu GU. Neonatal Outcomes in Children Born to Mothers with Severe Malaria, HIV, and Transfusion History: A Review. Elite Journal of Nursing and Health Science. 2024;2(3):38-58.
100. Obeagu EI, Obeagu GU. Assessing Platelet Functionality in HIV Patients Receiving Antiretroviral Therapy: Implications for Risk Assessment. Elite Journal of HIV. 2024;2(3):14-26.
101. Obeagu EI, Obeagu GU. Advancements in HIV Prevention: Africa's Trailblazing Initiatives and Breakthroughs. Elite Journal of Public Health. 2024;2(1):52-63.
102. Obeagu EI, Obeagu GU. Maternal Influence on Infant Immunological Responses to HIV: A Review. Elite Journal of Laboratory Medicine. 2024;2(1):46-58.
103. Obeagu EI, Obeagu GU. Counting Cells, Shaping Fates: CD4/CD8 Ratios in HIV. Elite Journal of Scientific Research and Review. 2024;2(1):37-50.